Otsuka's 24-month data for its IgA nephropathy (IGAN) drug shows it essentially stops disease progression, with some patients even improving their kidney function from baseline. Experts suggest this is a paradigm shift from treatment to what looks like a functional cure for a leading cause of kidney failure.

Apogee positions its 3- and 6-month dosing as a driver of superior adherence and better long-term outcomes, not just a lifestyle perk. The CEO draws a parallel to the psoriasis market, where less frequent dosing transformed the therapeutic landscape by encouraging more patients to start and stay on therapy.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Instead of targeting new biological pathways, Apogee enhances proven antibody therapies by extending their half-life. This shifts the competitive battleground from pure scientific discovery to patient adherence and lifestyle, aiming for quarterly or semi-annual dosing versus the current bi-weekly standard for market leaders.

The company's IgG-lowering drug is not a lifelong immunosuppressant but a single-use therapy. Its purpose is to enable a life-changing event—a kidney transplant—that would otherwise be impossible for highly sensitized patients. This "acute enabler" model simplifies long-term care, as patients revert to standard post-transplant protocols afterward.

The successful use of a surrogate endpoint (proteinuria reduction) for IgA nephropathy approvals has created a clear regulatory pathway. This blueprint is now being leveraged by developers to advance therapies for other previously untreatable renal diseases like FSGS, de-risking their clinical programs.

New drug formulations, like those for HIV prevention or cholesterol, create an internal depot that releases medicine over months. This dramatically improves efficacy by solving the massive problem of patient non-adherence to daily pills, representing a major shift in managing chronic conditions.

For RNAi and antisense therapies targeting chronic conditions like cardiovascular disease, the critical competitive advantage is durability, not just efficacy. The ability to offer infrequent dosing, such as twice-yearly injections, represents a significant step-change from daily medications and is the key factor expected to drive market adoption.

When asked about complex antibodies like ADCs and bispecifics, GSK's CSO emphasizes that extending a drug's duration is a primary innovation. He highlights a severe asthma treatment dosed just twice a year as a prime example of creating significant patient value before adding further engineering complexity.